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ABSTRACT PURPOSE: The clinically approved oncogenic BRAF inhibitor PLX4032 (vemurafenib) was 
shown to be a substrate of the ATP-binding cassette (ABC) transporter ABCB1. Here, we compared PLX4032 
and its structurally closely related precursor compound PLX4720 for their interference with ABCB1 and the 
ABCB1-mediated compound transport using docking and cell culture experiments. METHODS: For the 
docking study of PLX4032 and PLX4720 with ABCB1, we analysed binding of both compounds to mouse 
Abcb1a and to human ABCB1 using a homology model of human ABCB1 based on the 3D structure of 
Abcb1a. Naturally ABCB1 expressing cells including V600E BRAF-mutated and BRAF wild-type melanoma 
cells and cells transduced with a lentiviral vector encoding for ABCB1 were used as cell culture models. 
ABCB1 expression and function were studied by the use of fluorescent and cytotoxic ABCB1 substrates in 
combination with ABCB1 inhibitors. RESULTS: Docking experiments predicted PLX4032 to interact 
stronger with ABCB1 than PLX4720. Experimental studies using different cellular models and structurally 
different ABCB1 substrates confirmed that PLX4032 interfered stronger with ABCB1 function than 
PLX4720. For example, PLX4032 (20µM) induced a 4-fold enhanced rhodamine 123 accumulation compared 
to PLX4720 (20µM) in ABCB1-transduced UKF-NB-3 cells and reduced the IC50 for the cytotoxic ABCB1 
substrate vincristine in this model by 21-fold in contrast to a 9-fold decrease induced by PLX4720. 
CONCLUSIONS: PLX4032 exerted stronger effects on ABCB1-mediated drug transport than PLX4720.  This 
indicates that small changes in a molecule can substantially modify its interaction with ABCB1, a promiscuous 
transporter that transports structurally different compounds. 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
INTRODUCTION 
Metastatic melanoma belongs to the most 
aggressive cancer diseases with median survival 
times below 9 months. Activating BRAF (V600E) 
mutations are found in 30 to 70% of melanoma 
patients representing a novel therapeutic target for 
this disease (1). PLX4032 (vemurafenib), a 
specific inhibitor of V600E-mutated BRAF, 
caused high response rates and advanced overall 
and progression-free survival rates in metastatic 
melanoma patients carrying V600E BRAF 
mutations. Unfortunately, resistance to PLX4032 
develops quickly (2). 
PLX4032 was also found to be a substrate of 
the ATP-binding cassette (ABC) transporter 
ABCB1 (also known as P-glycoprotein or MDR1) 
(3-5). The interaction of drugs with ABCB1 is 
important because this transporter plays important 
roles in the passage of drugs, xenobiotics, and food 
constituents through cellular and tissue barriers 
and consequently in their absorption, distribution, 
and excretion. The clinical investigation of 
ABCB1 inhibitors had revealed that the use of 
compounds that interfere with ABCB1 function 
may result in toxic adverse events and complex 
pharmacokinetics and drug interactions that are 
difficult to predict (6,7). Moreover, ABCB1 is one 
of the most intensively studied intrinsic and 
acquired resistance mechanisms in cancer cells. It 
is known to cause resistance to major classes of 
anti-cancer drugs including vinca alkaloids, 
taxanes, and anthracyclines (6,7). 
PLX4720 is a structurally related progenitor of 
PLX4032 that displays the same mode of binding 
to V600E-mutated BRAF like PLX4032 (8,9). 
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It differs only in one phenyl ring from PLX4032 
(Figure 1). Here, we performed the first study that 
compared the effects of these two compounds on 
ABCB1 function. Docking studies suggested both 
PLX4032 and PLX4720 to bind to ABCB1 with 
PLX4032 displaying a slightly higher affinity. 
Verification experiments performed using a range 
of different cellular models and assays confirmed 
that PLX4032 exerts stronger effects on ABCB1 
than PLX4720.  
Figure 1. 2D ligand interaction diagram for PLX4032 (A) and PLX4720 (B) with mouse Abcb1a using MOE software. 
In this diagram, the energy cut-off for H-bond and ionic interactions were -0.5 kcal/mol and the maximum distance for 
nonbonded groups was 4.5 Å. The polar and non-polar interactions are indicated by pink or green coloured amino acids 
and hydrogen bonding is indicated by green dotted arrows. The proximity contour is the dotted line surrounding the 
ligand. It indicates the shape of the binding site and the available space to the more outward-facing parts of the ligand. 
Blue shadows in some amino acids indicate the receptor exposure differences by the size and intensity of the quoits discs. 
The directions of the shadow indicate the directions of the amino acids towards the ligands. The blue clouds around the 
ligand atoms indicate the solvent exposure. 
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MATERIALS AND METHODS 
Drugs 
Vincristine, verapamil, and PGP-4008 were 
obtained from Sigma-Aldrich (Deisenhofen, 
Germany). Rhodamine 123 was purchased from 
Merck Biosciences (Darmstadt, Germany). 
PLX4032 and PLX4720 were obtained from 
Selleck Chemicals via BIOZOL GmbH (Eching, 
Germany). Cisplatin was purchased from medac 
Gesellschaft für klinische Spezialpräparate mbH 
Wedel, Germany). 
ABCB1 docking studies 
The structure of Abcb1a, the mouse (Mus 
musculus) ortholog of the human ABCB1, had 
been co-crystalised with two stereo-isomers of 
cyclic hexapeptide inhibitors, cyclic-tris-(R)-
valineselenazole (QZ59-RRR) and cyclic-tris-(S)-
valineselenazole (QZ59-SSS) (10,11). For the 
docking study of PLX4032 and PLX4720 with 
ABCB1, we applied different approaches. We 
analysed binding of both compounds to mouse 
Abcb1a and (since high or medium resolution X-
ray structures of human ABCB1 are not available) 
to a homology model of human ABCB1 based on 
the 3D structure of Abcb1a (12). The X-ray 
structure of the mouse Abcb1a was downloaded 
from the protein data bank [http://www.rcsb.org]. 
Docking was carried out using 1) the MOE 
software (MOE, version 2010.10, Chemical 
Computing Group Inc. Montreal, Canada) and 2) 
the web application at http://pgp.althotas.com (12) 
which performs docking using the Autodock Vina 
software integrated in the Molecular Docking 
Server (http://www.dockingserver.com). 
The Mouse Abcb1a structure was loaded into 
the MOE software, where the crystal parameters 
were retained and hydrogens were added. 
Protonatable residues were titrated using default 
parameters. To prepare PLX4032 and PLX4720 
for docking, atomic charge and energy 
minimisation calculation was performed using 
SCF optimization through AM1 semiempirical 
method as implemented in the MOE software. In 
the MOE dock panel, the placement method was 
Triangle Matcher. The scoring methodology was 
set to London dG as the first and the second scoring 
functions. The refinement methodology was set to 
Forcefield, and finally, the 30 best scoring poses 
and the mean energies were retained. The binding 
site was defined in MOE software using the co-
crystalised ligand QZ59-RRR. The published X-
ray crystallography structures (10,11) were used to 
validate our docking model by comparing the 
geometries of the docked Abcb1a/QZ59-RRR 
structure and the structure of the Abcb1a/QZ59-
RRR complex from X-ray crystallography. The 
root-mean-square deviation (RMSD) value for this 
structure after superposing the docked and co-
crystal structure is 0.77. The absolute RMSD range 
without superposing is 0.89-6.2 for the top 30 
poses. Moreover, PDB structures of the ligands 
were prepared using MOE software and fed into 
the web server at http://pgp.althotas.com. 
Cell lines 
The neuroblastoma cell line UKF-NB-3 was 
established from bone marrow metastases of a 
neuroblastoma patient with MYCN-amplification 
(13). Its sub-line UKF-NB-3rVCR10 was 
established by its adaptation to growth in the 
presence of vincristine (10ng/mL) and is 
characterised by high ABCB1 expression (13,14). 
ABCB1-overexpressing (UKF-NB-3ABCB1, control 
cell line UKF-NB-3control) sub-lines of UKF-NB-3 
were established by lentiviral transduction with 
LeGO vectors as described previously (14-17). 
Vectors were derived using standard molecular 
cloning techniques as described previously (13,14, 
see also www.lentigo-vectors.de). 
The melanoma cell lines Colo-679, IPC-298, 
MelHO, RVH-421, and SK-Mel-30 were obtained 
from DSMZ (Braunschweig, Germany). 
All cell lines were propagated in Iscove’s 
modified Dulbecco’s medium (IMDM) 
supplemented with 10% FBS, 100IU/ml penicillin 
and 100mg/ml streptomycin at 37°C. 
Viability assay 
Cell viability was tested by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye reduction assay after 120h 
incubation, modified as described previously 
(14,17). All experiments were performed at least in 
triplicate. 
Flow cytometry and investigation of ABC 
transporter-mediated drug efflux 
An antibody directed against ABCB1 (Alexis 
Biochemicals via AXXORA Deutschland, 
Lörrach, Germany) and a secondary antibody 
labelled with Phycoerythrin (R&D, Wiesbaden, 
Germany) were used to detect ABCB1 expression 
by flow cytometry (FACSCalibur, BD 
Biosciences, Heidelberg, Germany). 
The ABCB1-mediated drug efflux and wash-
out kinetics were determined as described before 
(14,17). To investigate ABCB1-mediated 
substance efflux, the cells were pre-incubated for 
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30min with different drug concentrations. 
PGP4008 was used as control inhibitor of ABCB1-
mediated efflux. 0.1µM rhodamine 123 was added 
for another 30 min. Then, cell culture medium was 
removed, cells were washed three times with PBS, 
and fresh medium containing drugs was added. 
After another 45min, the cellular fluorescence was 
analysed by flow cytometry. Rhodamine 123 was 
detected at the FL1 channel. 
For wash out experiments, UKF-NB-3ABCB1 
cells were incubated for 1h with rhodamine 123 
0.1µM together with different drug concentrations 
or with PGP4008. Subsequently, cells were 
washed, resuspended in supplemented medium, 
and the cellular fluorescence was measured at 
different time points (t0, t5, t15, t30, t60, t120 minutes) 
by flow cytometry. 
Determination of ATPase activity 
The ATPase activity of ABCB1 was determined 
using membrane preparations (BD Biosciences, 
Heidelberg, Germany) and an established kit (BD 
Biosciences, Heidelberg, Germany) following the 
manufacturer’s instruction. 
STATISTICAL ANALYSIS 
Two groups were compared by t-test. More groups 
were compared by ANOVA with subsequent 
Student-Newman-Keuls test. 
RESULTS 
Docking studies on the interaction of PLX4032 
and PLX4720 with ABCB1 
Two docking approaches were used (web server 
docking, MOE) to predict the interaction of 
PLX4032 and PLX4720 with ABCB1. These 
approaches were applied using the X-ray structure 
of mouse Abcb1a, the mouse ortholog of the 
human ABCB1, or a homology model of human 
ABCB1.  
The interactions of PLX4032 and PLX4720 
with mouse Abcb1a are illustrated in Figure 1. 
Most amino acids in the active site are lipophilic. 
For PLX4032, docking energies in the top ten 
poses are quite high; energy of the top pose is -14.6 
according to Table 1. Ligand interactions of the top 
ten poses showed that Phe974 is actively involved 
in several poses. Further examination of the top ten 
poses renditions indicated that the placement of the 
π-π interaction of Phe974 is qualitatively 
preserved. Figure 1A is the structure of the top pose 
and shows the pyridine and pyrrole rings in the 
pyrrolo-pyridine in a strong arene-arene interaction 
to Phe 974. The large and intense blue shadows 
surrounding the amino acids Phe 332, Val 978, Tyr 
303, Gln 721, Phe 724, and Phe 974, indicate that 
in the absence of the ligand these amino acids are 
highly exposed to the solvent, but the presence of 
the ligand greatly reduces the solvent accessible 
surface area. The amino acids Met 68, Leu 64, and 
Tyr 949 are also involved but to a lesser extent. The 
chlorobenzene group on the left as well as the 
propyl side chain on the sulphonamide illustrate 
degrees of solvent exposure (Figure 1A). In 
PLX4720, the propane sulphonamide group is also 
exposed to solvent (Figure 1B). The 
difluoroaniline has a strong arene-hydrogen bond 
interaction to Val 978, while the chloro-pyrrolo 
pyridine (left) has an arene-arene interaction to Phe 
71 through the pyridine ring and arene-hydrogen 
bond to Phe 332 through the pyrrole ring. The 
receptor exposure differences are the highest for 
Phe 332 and Val 978 (Figure 1B). 
The calculated docking energies for the 30 top 
poses are presented in Table 1 for mouse Abcb1a 
and for human ABCB1. PLX4032 has a stronger 
interaction energy with both forms, as indicated by 
comparing the energies of the top pose and the 
average of the 30 top poses using both docking 
methods (web server docking, MOE) (Table 1).  
Table 1. Protein interaction energies (kcal/mol) of top scoring poses of docking mouse Abcb1a or human ABCB1 with 
PLX4032 and PLX4720 by two different approaches. The average of the 30 top scoring poses is reported; values in 
brackets are the minimum and the maximum energies. 
Receptor 
web server docking 
(http://pgp.althotas.com/) MOE 
PLX4032 PLX4720 PLX4032 PLX4720 
mouse Abcb1a -10.7 -9.0 -10.6 
(-14.6, -6.72) 
-9.91 
(-13.73, -5.86) 
human ABCB1 -11.2 -10.3 -9.10 
(-11.0, -7.42) 
-8.78 
(-10.1, -8.26) 
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The distances between the important groups 
in PLX4032 or PLX4720 and the interacting 
residues in mouse Abcb1a are shown in Table 2. 
Despite that docking scores are often not very well 
correlated with the actual biological affinity, given 
that PLX4032 has one additional aromatic ring in 
comparison with PLX4720 and this can potentially 
improve binding affinity in the absence of steric 
hindrance, taken together, the docking results 
indicate a stronger interaction with ABCB1 for 
PLX4032 than for PLX4720. 
Effects of PLX4032 and PLX4720 on ABCB1 
function 
PLX4032 and PLX4720 both enhanced 
accumulation of the fluorescent ABCB1 substrate 
rhodamine 123 in UKF-NB-3ABCB1 cells (but not in 
empty vector-transduced control UKF-NB-3Cer2 
cells or non-transduced parental UKF-NB-3 cells 
that lack ABCB1 expression, not shown) in a 
concentration-dependent manner (Figure 2A). 
PLX4032 (20µM) induced a 4-fold enhanced 
rhodamine 123 accumulation compared to 
PLX4720 (20µM). Neither PLX4032 nor 
PLX4720 affected ABCB1 expression in 
concentrations up to 20µM after incubation for up 
to 5 days (data not shown). 
Next, we determined the rhodamine 123 wash-
out kinetics in the presence of PLX4032 or 
PLX4720. Cells were incubated with rhodamine 
123 in the presence of PLX4032 or PLX4720 for 
60 min. Subsequently, cells were washed and the 
cellular fluorescence was monitored at different 
time points after the wash-out by flow cytometry. 
The rhodamine 123 fluorescence rapidly decreased 
after wash-out of PLX4032 or PLX4720 (Figure 
2B). Moreover, both compounds increased the 
ABCB1 ATPase activity (Figure 2C). 
Table 2. Distances between groups in PLX4032 or PLX4720 and the corresponding protein residues in mouse Abcb1a 
as indicated by the MOE docking approach 
Ligand Residue Group in PLX4720 Distance (Å) 
PLX4720 Phe332 N
Cl
3.50 
Val978 F
F
4.01 
Phe71 N
Cl
3.61 
Ligand Residue Group in PLX4032 Distance (Å) 
PLX4032 Phe974 N 3.64 
Phe974 
N
H 3.99 
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Figure 2. Interference of PLX4032 and PLX4720 with ABCB1 activity. A) Concentration-dependent influence of 
PLX4032 or PLX4720 on rhodamine 123 (0.1 µM) fluorescence in UKF-NB-3ABCB1 cells (Cells were pre-incubated for 
30min with the indicated PLX4032 concentrations. Then, 0.1µM rhodamine 123 was added for another 30 min. After 
this, cell culture medium was removed, cells were washed three times with PBS, and fresh medium containing PLX4032 
was added. After another 45min, the cellular fluorescence was analysed by flow cytometry), B) time kinetics of 
rhodamine 123 (0.1 µM) fluorescence in UKF-NB-3ABCB1 cells in the presence of PLX4032 or PLX4720 after a 60 min 
pre-incubation period with subsequent wash-out of extracellular rhodamine 123 and PLX4032 or PLX4720 (control = 
rhodamine 123 incubation in the absence of drugs). C) ABCB1 ATPase activity in isolated membranes in the presence 
of PLX4032 or PLX4720 (control = activity in the absence of drugs). Verapamil, a known ABCB1 substrate, was used 
for comparison. * P < 0.05 relative to non-treated controls 
PLX4032 and PLX4720 also increased the 
toxicity of the ABCB1 substrate vincristine in 
UKF-NB-3ABCB1 cells in a concentration-
dependent manner (Figure 3, Suppl. Table 1). In 
accordance with the cellular rhodamine 123 
accumulation data, PLX4032 caused substantially 
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stronger effects than PLX4720 (Figure 3, Suppl. 
Table 1). Neither PLX4032 nor PLX4720 affected 
vincristine toxicity in non-transduced UKF-NB-3 
cells (Figure 3, PLX4032, Suppl. Table 2; 
PLX4720, Suppl. Table 3) or in UKF-NB-3 cells 
transduced with a control vector (Figure 3, 
PLX4032, Suppl. Table 4; PLX4720, Suppl. Table 
5). 
Effects of PLX4032 and PLX4720 on melanoma 
cells in combination with the cytotoxic ABCB1 
substrate vincristine 
PLX4032 and PLX4720 were further investigated 
in combination with the cytotoxic ABCB1 
substrate vincristine in two melanoma cell lines 
expressing wild-type BRAF (IPC-298, SK-Mel-
30). Both cell lines expressed ABCB1. The 
ABCB1 inhibitor PGP4008 (Table 3) and 
PLX4032 and PLX4720 decreased the vincristine 
IC50s in both cell lines (Table 4). Again, PLX4032 
exerted stronger effects than PLX4720. 
Effects of PLX4032 in combination with 
structurally different ABCB1 substrates in 
different ABCB1 expressing cells 
ABCB1 transports a broad spectrum of structurally 
different substances (6). Therefore, we 
investigated the effects of PLX4032 and PLX4720 
on the sensitivity of the ABCB1-expressing cell 
lines UKF-NB-3ABCB1 and UKF-NB-3rVCR10 to 
the cytotoxic ABCB1 substrates vincristine, 
paclitaxel, and actinomycin D. The non-ABCB1 
substrate CDDP was used as negative control. Both 
cell lines were sensitised by both compounds to all 
three ABCB1 substrates but not to cisplatin (Figure 
4, Suppl. Table 6). In UKF-NB-3ABCB1 cells, 
PLX4032 10µM reduced the IC50 for vincristine by 
37.81-fold, for paclitaxel by 7.61-fold, and for 
actinomycin D by 16.28-fold. PLX4720 10µM 
caused in UKF-NB-3ABCB1 cells an IC50 reduction 
by 6.88-fold for vincristine, by 2.73-fold for 
paclitaxel, and by 3.50-fold for actinomycin D. In 
UKF-NB-3rVCR10 cells, PLX4032 10µM 
decreased the vincristine IC50 by 27.98-fold, the 
paclitaxel IC50 by 4.10-fold, and the actinomycin D 
IC50 by 6.06-fold, while PLX4720 reduced the 
respective IC50 values by 7.19-fold (vinctistine), 
1.77-fold (paclitaxel), and 3.68-fold (actinomycin 
D) (Figure 4, Suppl. Table 6). The compounds did
neither sensitise UKF-NB-3 cells nor UKF-NB-3 
cells transduced with a control vector (serving as 
vector control for UKF-NB-3ABCB1 cells) to 
toxicity induced by vincristine, paclitaxel, 
actinomycin D, or cisplatin (Figure 4, Suppl. Table 
7). Taken together, these data show that PLX4032 
and PLX4720 interfere with a range of structurally 
different ABCB1 substrates and that PLX4032 
consistently exerts stronger effects on the ABCB1-
mediated compound transport. 
DISCUSSION 
PLX4032, an inhibitor of V600E-mutated BRAF, 
demonstrated clinical efficacy for the treatment of 
V600E-mutated melanoma (2) and was shown to 
be a substrate of ABCB1 (3-5), an ABC transporter 
that is involved in the regulation of the absorption, 
distribution, and excretion of drugs and 
xenobiotics as well as in cancer cell drug resistance 
(6). 
Here, we compared PLX4032 and its 
structurally related progenitor compound 
PLX4720 for their effects on ABCB1. First, we 
performed docking experiments. The interaction 
energies and the 2D representation of the 
interaction plot for the top poses indicated that 
PLX4032 has a stronger interaction with ABCB1 
than PLX4720. Both compounds interfere with 
ABCB1’s Phe 332 and Val 978, and in addition 
PLX4032 has strong interaction with Phe 974. 
The docking results were experimentally 
confirmed using UKF-NB-3 neuroblastoma cells 
transduced with a lentiviral vector encoding for 
ABCB1 and ABCB1-expressing UKF-NB-
3rVCR10 cells. PLX4032 and PLX4720 interfered 
with the transport of compounds from structurally 
different classes including the fluorescence dye 
rhodamine 123 and the cytotoxic anti-cancer drugs 
vincristine, paclitaxel, and actinomycin D. These 
findings are quite remarkable because they show 
that small changes in a molecule like PLX4032 can 
result in a substantial change in its affinity to 
ABCB1 despite the tremendous promiscuity of this 
transporter that recognises substrates from a broad 
range of structurally very different compounds (6). 
Compounds that interfere with ABCB1 function 
may modify the pharmacokinetics of co-
administered substances. This may result in toxic 
adverse events and unpredictable drug interactions 
(7). Therefore, compounds that display less 
interaction with ABCB1 may be favourable, in 
particular if administered at the same time as 
cancer-unrelated drugs. The situation may be less 
clear regarding anti-cancer therapy regimens that 
contain PLX4032 in combination with other anti-
cancer drugs as proposed previously (18).  
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Figure 3. Influence of PLX4032 and PLX4720 on the vincristine sensitivity of UKF-NB-3 cells transduced with a 
lentiviral vector (UKF-NB-3ABCB1), UKF-NB-3 cells, and UKF-NB-3 cells transduced with an empty lentiviral control 
vector (UKF-NB-3control). Cell viability was determined after 5 days of incubation by MTT assay. The ABCB1 inhibitor 
PGP4008 (2.5µM) served as control. The values are presented in the Suppl. Tables 1-5. * P < 0.05 relative to vincristine 
alone. 
In combination with non-ABCB1 substrates and/or 
for the treatment of ABCB1-negative cells, the 
interference of PLX4032 with ABCB1 bears the 
risk of unfavourable side-effects due to the 
modification of the body distribution of 
xenobiotics and cancer-unrelated drugs. However, 
combinations of PLX4032 with other anti-cancer 
drugs that are ABCB1 substrates may result in 
synergistic effects due to inhibition of ABCB1-
mediated drug efflux in ABCB1-expressing cancer 
cells. 
PLX4032 and PLX4720 also enhanced the 
effects of vincristine in the ABCB1-expressing 
wild-type BRAF melanoma cell lines IPC-298 and 
SK-MEL-30. In addition, PLX4032 increased the 
toxicity of the ABCB1 substrate vincristine in 
V600E BRAF-mutated melanoma cells (Figure 5) 
although we did not define the driver mechanisms 
underlying this combined effect.
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Table 4. Influence of PLX4032 (20µM) or PLX4720 (20µM) on the vincristine (ABCB1 substrate) concentrations 
that reduce cell viability by 50% (IC50) in the BRAF wild-type melanoma cell lines IPC298 and SK-MEL-30 that 
both express ABCB1. 
IC50 vincristine 
(ng/ml)  
IC50 vincristine in the 
presence of 
PLX4032/PLX4720 
cell viability in the 
presence of PLX4032 or 
PLX4720 alone 
(% control) 
fold sensitisation1
PLX4032 
IPC298 2.74 ± 0.39 0.54 ± 0.07* 73 ± 7 5.11 
SK-MEL-30 4.57 ± 1.49 0.42 ± 0.07* 85 ± 9 10.82 
PLX4720 
IPC298 2.74 ± 0.39 0.83 ± 0.08* 57 ± 10 3.32 
SK-MEL-30 4.57 ± 1.49 1.50 ± 0.62* 73 ± 5 3.04 
1 IC50 vincristine/ IC50 vincristine in the presence of PLX4032 or PLX4720, respectively; * p < 0.05 relative to 
vincristine alone 
Figure 4. Effects of PLX4032 (10µM) and PLX4720 (10µM) on the sensitivity of UKF-NB-3 cells transduced with a 
lentiviral vector (UKF-NB-3ABCB1), ABCB1-expressing UKF-NB-3rVCR10 cells, UKF-NB-3 cells, and UKF-NB-3 cells 
transduced with an empty lentiviral control vector (UKF-NB-3control) to structurally different cytotoxic ABCB1 substrates. 
Cell viability was determined after 5 days of incubation by MTT assay. Cisplatin that is not an ABCB1 substrate served 
as control. The values are presented in the Suppl. Tables 6 and 7. * P < 0.05 relative to the respective cytotoxic drug 
alone. 
A rapid decrease of cellular fluorescence 
mediated by the ABCB1 substrate rhodamine 123 
was detected after the wash-out of PLX4032 and 
PLX4720. Also, both compounds stimulated the 
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ATPase activities of ABCB1. These findings may 
suggest that PLX4032 and PLX4720 are ABCB1 
substrates. Thus, they are in accordance with recent 
publications that showed that PLX4032 is a 
ABCB1 substrate (3,4). Notably, the interaction of 
compounds like PLX4032 and PLX4720 with 
ABCB1 may depend on the cellular context since 
PLX4720 was recently shown not to affect ABCB1 
function in Ras-NIH 3T3/Mdr cells (19). 
In conclusion, we show that PLX4032 exerts 
stronger effects on ABCB1 than its structurally 
very similar progenitor PLX4720. The findings 
demonstrate that small changes in a molecule can 
substantially modify its interaction with ABCB1 
although ABCB1 is an extremely promiscuous 
transporter that transports a broad range of 
structurally different compounds. 
Figure 5. Influence of PLX4032 on the sensitivity of 
ABCB1- and ABCC1-expressing V600E BRAF-
mutated melanoma cells to the cytotoxic ABCB1 and 
ABCC1 substrate vincristine. Viability of Colo-679 or 
MelHO melanoma cells after 48h incubation with 
vincristine (10ng/ml), PLX4032 (10µM), or vincristine 
(10ng/ml) + PLX4032 (10µM) relative to non-treated 
control. * P < 0.05 relative to non-treated controls; # P < 
0.05 relative to vincristine (10ng/ml) treatment; † P < 
0.05 relative to PLX4032 (10µM) treatment. 
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Suppl. Table 1. Influence of PLX4032, PLX4720 or the ABCB1 inhibitor PGP4008 on the concentration of the 
ABCB1 substrate vincristine that decreases the viability of ABCB1-expressing UKF-NB-3ABCB1 cells by 50% (IC50). 
cell viability in the absence 
of vincristine (%) 
IC50 vincristine 
(ng/mL)1 
fold sensitisation relative to vincristine 
alone 
PLX4032 (µM) 
0 100.00 ± 0.00 6.71 ± 0.67 1.00 
0.625 91.56 ± 10.38 6.33 ± 1.72 1.06 
1.25 82.88 ± 7.46 3.50 ± 0.39* 1.92 
2.5 80.77 ± 4.14 1.28 ± 0.42* 5.24 
5 89.86 ± 5.65 1.06 ± 0.20* 6.33 
10 82.75 ± 14.95 0.89 ± 0.16* 7.54 
20 90.69 ± 4.42 0.32 ± 0.10* 20.97 
PGP4008 2.5µM 79.42 ± 14.29 0.16 ± 0.05* 41.94 
PLX4720 (µM) 
0 100.00 ± 0.00 6.18 ± 0.17 1.00 
0.625 100.61 ± 6.97 6.54 ± 1.98 0.94 
1.25 89.23 ± 9.90 5.57 ± 0.35 1.11 
2.5 81.50 ± 9.19 4.88 ± 1.36 1.26 
5 100.00 ± 16.87 3.02 ± 0.22* 2.05 
10 75.86 ± 7.00 2.47 ± 0.61* 2.50 
20 76.00 ± 11.31 0.70 ± 0.05* 8.83 
PGP4008 2.5µM 82.24 ± 20.45 0.12 ± 0.03* 51.50 
 1 in the presence of the indicated PLX4032, PLX4720, or PGP4008 concentrations 
* p < 0.05 relative to vincristine alone
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Suppl. Table 2. Influence of PLX4032 or the ABCB1 inhibitor PGP4008 on the concentration of the ABCB1 substrate 
vincristine that decreases the viability of UKF-NB-3 cells by 50% (IC50). 
PLX4032 (µM) cell viability in the 
absence of vincristine (%) 
IC50 vincristine 
(ng/mL)1 
fold sensitisation relative to vincristine 
alone 
0 100.00 ± 0.00 0.14 ± 0.03 1.00 
0.625 95.25 ± 7.88 0.14 ± 0.06 1.00 
1.25 87.19 ± 9.71 0.17 ± 0.04 0.82 
2.5 74.61 ± 8.69 0.12 ± 0.03 1.17 
5 75.28 ± 7.79 0.13 ± 0.05 1.08 
10 70.37 ± 6.21 0.15 ± 0.05 0.93 
20 45.32 ± 8.17 0.13 ± 0.05 1.08 
PGP4008 (µM) 
2.5 77.82 ± 14.09 0.12 ± 0.05 1.17 
1 in the presence of the indicated PLX4032 or PGP4008 concentrations 
Suppl. Table 3. Influence of PLX4720 or the ABCB1 inhibitor PGP4008 on the concentration of the ABCB1 substrate 
vincristine that decreases the viability of UKF-NB-3 cells by 50% (IC50). 
PLX4720 (µM) cell viability in the 
absence of vincristine (%) 
IC50 vincristine 
(ng/mL)1 
fold sensitisation relative to vincristine 
alone 
0 100.00 ± 0.00 0.17 ± 0.06 1.00 
0.625 95.19 ± 12.38 0.16 ± 0.03 1.06 
1.25 82.56 ± 9.96 0.16 ± 0.05 1.06 
2.5 88.15 ± 11.16 0.19 ± 0.02 0.89 
5 80.06 ± 9.22 0.20 ± 0.04 0.85 
10 61.51 ± 12.87 0.15 ± 0.05 1.13 
20 40.83 ± 10.33 0.18 ± 0.06 0.94 
PGP4008 (µM) 
2.5 74.64 ± 16.51 0.15 ± 0.03 1.13 
1 in the presence of the indicated PLX4720 or PGP4008 concentrations 
Suppl. Table 4. Influence of PLX4032 or the ABCB1 inhibitor PGP4008 on the concentration of the ABCB1 substrate 
vincristine that decreases the viability of UKF-NB-3 cells transduced with an empty control vector (as comparison to 
UKF-NB-3ABCB1) by 50% (IC50). 
PLX4032 (µM) cell viability in the 
absence of vincristine (%) 
IC50 vincristine 
(ng/mL)1 
fold sensitisation relative to vincristine 
alone 
0 100.00 ± 0.00 0.18 ± 0.06 1.00 
0.625 92.86 ± 11.74 0.16 ± 0.04 1.13 
1.25 80.49 ± 10.82 0.13 ± 0.07 1.38 
2.5 81.19 ± 9.96 0.18 ± 0.01 1.00 
5 78.67 ± 4.51 0.12 ± 0.08 1.50 
10 72.57 ± 4.19 0.19 ± 0.02 0.95 
20 40.67 ± 7.73 0.12 ± 0.04 1.50 
PGP4008 (µM) 
2.5 76.68 ± 15.01 0.16 ± 0.06 1.13 
1 in the presence of the indicated PLX4032 or PGP4008 concentrations 
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Suppl. Table 5. Influence of PLX4720 or the ABCB1 inhibitor PGP4008 on the concentration of the ABCB1 substrate 
vincristine that decreases the viability of UKF-NB-3 cells transduced with an empty control vector (as comparison to 
UKF-NB-3ABCB1) by 50% (IC50). 
PLX4720 (µM) cell viability in the 
absence of vincristine (%)
IC50 vincristine 
(ng/mL)1 
fold sensitisation relative to vincristine 
alone 
0 100.00 ± 0.00 0.22 ± 0.07 1.00 
0.625 90.26 ± 7.84 0.20 ± 0.08 1.10 
1.25 96.88 ± 5.95 0.19 ± 0.03 1.16 
2.5 77.89 ± 6.09 0.16 ± 0.06 1.38 
5 75.31 ± 9.01 0.25 ± 0.04 0.88 
10 66.28 ± 14.72 0.18 ± 0.05 1.22 
20 35.16 ± 12.63 0.21 ± 0.05 1.05 
PGP4008 (µM) 
2.5 79.65 ± 16.96 0.19 ± 0.06 1.16 
1 in the presence of the indicated PLX4720 or PGP4008 concentrations 
Suppl Table 6. Viability of the ABCB1-expressing cell lines UKF-NB-3ABCB1 or UKF-NB-3rVCR10 after treatment with 
vincristine, paclitaxel, actinomycin D (cytotoxic ABCB1 substrates), or cisplatin (no ABCB1 substrate) in the absence 
or presence of PLX4032 (10µM) or PLX4720 (10µM), determined by MTT assay after a 5 day incubation period. 
Concentration that inhibits cell viability by 50% (IC50) 
Cell line vincristine 
(ng/mL)
paclitaxel 
(ng/mL)
actinomycin 
D (ng/mL)
cisplatin 
(ng/mL) 
UKF-NB-3ABCB1 6.05 ± 0.48 16.89 ± 1.65 0.70 ± 0.04 136 ± 16 
+ PLX4032 (91 ± 3%)1 0.16 ± 0.052 
(37.81)3 
2.22 ± 0.622 
(7.61) 
0.043 ± 0.0042 
(16.28) 
111 ± 17 
(1.23) 
+ PLX4720 (76 ± 5%) 0.88 ± 0.232 
(6.88) 
6.18 ± 0.892
(2.73) 
0.20 ± 0.032 
(3.50) 
132 ± 242 
(1.03) 
UKF-NB-3rVCR10 34.42 ± 5.80 19.64 ± 2.07 3.09 ± 1.21 215 ± 26 
+ PLX4032 (90 ± 3%) 1.23 ± 0.262 
(27.98) 
4.79 ± 0.632 
(4.10) 
0.51 ± 0.202 
(6.06) 
201 ± 10 
(1.07) 
+ PLX4720 (83 ± 10%) 4.79 ± 0.632 
(7.19) 
11.07 ± 1.532 
(1.77) 
0.84 ± 0.152 
(3.68) 
199 ± 232 
(1.08) 
1 Cell viability in the presence of PLX4032 (10µM) or PLX4720 (10µM) alone relative to non-treated cells 
2 p < 0.05 relative to the IC50 value in the absence of PLX4032 and PLX4720 
3 Fold sensitisation relative to cytotoxic drug alone 
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Suppl. Table 7. Viability of UKF-NB-3 or UKF-NB-3control (UKF-NB-3 cells transduced with an empty vector serving 
as control to UKF-NB-3ABCB1) cells after treatment with vincristine, paclitaxel, actinomycin D (cytotoxic ABCB1 
substrates), or cisplatin (no ABCB1 substrate) in the absence or presence of PLX4032 (10µM) or PLX4720 (10µM), 
determined by MTT assay after a 5 day incubation period. 
Concentration that inhibits cell viability by 50% (IC50) 
Cell line vincristine 
(ng/mL) 
paclitaxel 
(ng/mL) 
actinomycin 
D (ng/mL) 
cisplatin 
(ng/mL) 
UKF-NB-3 0.14 ± 0.05 1.68 ± 0.12 0.083 ± 0.002 115 ± 3 
+ PLX4032 (72 ± 7%)1 0.12 ± 0.03 
(1.17)2 
1.51 ± 0.30 
(1.11) 
0.080 ± 0.007 
(1.04) 
103 ± 13 
(1.12) 
+ PLX4720 (64 ± 7%) 0.11 ± 0.04 
(1.27) 
1.65 ± 0.14
(1.02) 
0.084 ± 0.009 
(1.02) 
136 ± 20 
(0.85) 
UKF-NB-3control 0.12 ± 0.02 1.38 ± 0.17 0.12 ± 0.03 82 ± 3 
+ PLX4032 (88 ± 3%) 0.10 ± 0.03 
(1.20) 
1.50 ± 0.29 
(0.92) 
0.11 ± 0.02 
(1.09) 
85 ± 11 
(0.96) 
+ PLX4720 (75 ± 4%) 0.13 ± 0.02 
(0.92) 
1.56 ± 0.23 
(0.88) 
0.13 ± 0.03 
(0.92) 
99 ± 21 
(0.83) 
1 Cell viability in the presence of PLX4032 (10µM) or PLX4720 (10µM) alone relative to non-treated cells 
2 Fold sensitisation relative to cytotoxic drug alone 
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Table 3. ABCB1 expression in melanoma cells and the influence of the ABCB1 inhibitor PGP4008 (2.5µM) on the concentration of the ABCB1 substrate 
vincristine that decreases the viability of melanoma cells by 50% (IC50). 
ABCB1 expression IC50 vincristine (ng/ml) 
Cell line BRAF 
status 
RFU1 + PGP4008 fold 
sensitisation2 
IPC298 wild-type yes 27 ± 9 2.74 ± 0.39 0.75 ± 0.423 (79 ± 3)4 3.65
SK-Mel-30 wild-type yes 88 ± 15  4.57 ± 1.49 0.92 ± 0.333 (91 ± 10) 4.99 
1 RFU, relative fluorescence units (background fluorescence determined by the use of an isotype control was substracted) 
2 IC50 vincristine/ IC50 vincristine in the presence of PGP4008 
3 P < 0.05 relative to vincristine alone 
4 cell viability (% non-treated control) in the presence of PGP4008 alone 
